PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Am J Med Genet A. Author manuscript; available in PMC 2010 March 3.
Published in final edited form as:
PMCID: PMC2831198
NIHMSID: NIHMS164253

Sclerocornea Associated With the Chromosome 22q11.2 Deletion Syndrome

Abstract

Reported ocular findings in the 22q11.2 deletion syndrome (which encompasses the phenotypes of DiGeorge, velocardiofacial, and Takao (conotruncal-anomaly-face) syndromes) have included posterior embryotoxon (prominent, anteriorly displaced Schwalbe’s line at the corneal limbus or edge), retinal vascular tortuosity, eyelid hooding, strabismus, and astigmatism. We present seven 22q11.2 patients from multiple centers with sclerocornea, an eye finding previously unreported in the literature. Four boys and three girls were identified with sclerocornea, systemic DGS/VCFS findings, and fluorescence in situ hybridization (FISH)-confirmed microdeletion at chromosome 22q11.2. FISH diagnosis was perinatal in six patients but at 2 years of age in one child. Sclerocornea was bilateral in five patients. Findings included descemetocele (five eyes), microophthalmos (one eye), iridocorneal adhesions (one bilateral case), and severe anterior segment dysgenesis (one eye). Two patients underwent bilateral corneal transplantation; another two were scheduled for possible unilateral transplant. Sclerocornea is a static congenital condition in which the cornea is opaque and vascularized and resembles the sclera. The novel finding of sclerocornea suggests that a genetic locus at 22q11.2 may be involved in anterior segment embryogenesis. In most of our patients, the diagnostic process was underway, but in one patient 22q11.2 deletion was not suspected until after the child had already been undergoing treatment for sclerocornea for 2 years. Sclerocornea should be added to the clinical manifestations of the 22q11.2 deletion syndrome. Ophthalmologists diagnosing sclerocornea in children with systemic findings suggestive of 22q11.2 deletion should ensure appropriate genetic referral.

Keywords: sclerocornea, corneal opacity, chromosome 22q11.2 deletion syndrome, DiGeorge syndrome, velocardiofacial syndrome, Opitz G/BBB syndrome, Cayler cardiofacial syndrome, Catch 22

INTRODUCTION

The chromosome 22q11.2 deletion syndrome encompasses phenotypes previously called DiGeorge syndrome, velocardiofacial (Shprintzen) syndrome, Conotruncal anomaly face (Takao) syndrome, and some cases of autosomal dominant Optiz G/BBB syndrome and Cayler cardiofacial syndrome. [Driscoll et al., 1993; Wilson et al., 1993; Matsuoka et al., 1994; McDonald-McGinn et al., 1995; LaCassie and Arriaza, 1996; Wulfsberg et al., 1996; McDonald-McGinn et al., 1997a,b, 1999]. The 22q11.2 deletion syndrome occurs in about 1 in 4,000 live births. [Devriendt et al., 1998; Oskarsdottir et al., 2004] and is a contiguous gene deletion syndrome detected by fluorescence in situ hybridization (FISH) in 95% of the cases.

The clinical manifestations are varied and include congenital heart malformations (74%), in particular conotruncal malformations (tetralogy of Fallot, interrupted aortic arch, ventricular septal defect, and truncus arteriosus), palatal abnormalities (69%) such as velopharyngeal incompetence, submucous cleft palate and overt cleft palate, characteristic facial features in the majority of Caucasians (e.g., overfolded/squared-off helices, bulbous nasal tip, small mouth and chin), learning difficulties (70–90%), and thymus and parathyroid hypoplasia with immune (T-cell) deficiency (77%) and hypocalcemia (50%). [McDonald-McGinn et al., 1996,1997a, 1999a, 2001; Sullivan, 2004; Bassett et al., 2005; McDonald-McGinn et al., 2005, 2006] Other findings include feeding problems, growth hormone deficiency, autoimmune disorders, hearing loss, seizures, and renal, musculoskeletal, and laryngotracheoesophageal abnormalities.

Ophthalmologic findings in the 22q11.2 deletion syndrome have included posterior embryotoxon (a prominent, anteriorly displaced Schwalbe’s line at the corneal limbus or edge), retinal vascular tortuosity, eyelid hooding, strabismus, and astigmatism. [Fitch, 1983; Shprintzen et al., 1985; Beemer et al., 1986; Mansour et al., 1987; Ryan et al., 1997; Forbes et al., 2006] We present a multicenter case series of seven patients with the 22q11.2 deletion syndrome and sclerocornea, a finding previously unreported in the literature.

MATERIALS AND METHODS

Clinical data were collected on seven patients with sclerocornea and the 22q11.2 microdeletion diagnosed by FISH presenting to the Children’s Hospital of Philadelphia, Philadelphia, PA; Children’s Healthcare of Atlanta at Egleston, GA; the University of Iowa, Iowa City, IA; the Lucile Salter Packard Children’s Hospital, Palo Alto, CA; and the Marshfield Clinic, Saint Joseph’s Hospital, Marshfield, WI. All patients were examined by an ophthalmologist. FISH diagnosis was carried out using the N25 probe or the TUPLE 1 probe in the chromosome 22q11.2 region to demonstrate a single 22 homolog signal, contrasted with a control probe, for example, ARSA in 22q12.3, present on both chromosome 22 homologs.

The study was approved by the Institutional Review Board of the University of Pennsylvania/Children’s Hospital of Philadelphia as part of studies on patients with the Chromosome 22q11.2 deletion syndrome, and the study data were handled in compliance with HIPAA regulations.

RESULTS

Four boys and three girls were identified with sclerocornea, systemic 22q11.2 deletion findings, and FISH-confirmed microdeletion at 22q11.2 (Table I). Diagnosis of the 22q11.2 deletion was perinatal in six patients and at 2 years of age in one patient (Patient 3), who had undergone corneal transplantation earlier in life and presented with a perforated corneal ulcer requiring surgical repair, after which a post-operative fever work-up led to the discovery of systemic abnormalities and the 22q11.2 microdeletion. Sclerocornea was bilateral in five patients. Additional ocular findings included descemetocele (five eyes), microophthalmos (one eye), iridocorneal adhesions (one bilateral case), and severe anterior segment dysgenesis (one eye). Three patients underwent corneal transplantation (two bilateral, one unilateral), and another patient was scheduled for a possible unilateral transplant. Figure 1

Fig. 1
Sclerocornea of the right eye in a newborn with Chromosome 22q11.2 microdeletion (Patient 7). The limbus (corneal–scleral border) is poorly defined and there is opacification of the inferior cornea with extension up into the visual axis. This ...
TABLE I
Clinical Findings of Seven Patients With 22q11.2 Deletion and Sclerocornea

DISCUSSION

Sclerocornea is a congenital, non-progressive, non-inflammatory condition in which one or both corneas demonstrate some degree of opacification coupled with flattening of the normal corneal curvature. In all patients, opacification is more pronounced in the corneal periphery with varying involvement of the visual axis, in contrast with the primarily central opacification found in Peter anomaly. Sclerocornea is most commonly bilateral and asymmetric, although unilateral cases have been reported. [Krachmer et al., 1997] Flattening of corneal curvature may be severe; indeed, corneal curvatures equal to or less than scleral curvature are pathognomonic for the condition. [Desvignes et al., 1967] The association between opacification and flattening is so strong that most authors consider sclerocornea and cornea plana to be phenotypic manifestations of the same condition.

Sclerocornea may be sporadic or familial, without gender predilection, and when inherited, the recessive form typically demonstrates a more severe phenotype than the dominant form. [Bloch, 1965; Howard and Abrahams, 1971; Eliott et al., 1985; Tahvanainen et al., 1995] Associated genetic loci that have been reported include Xp22.31 when sclerocornea is present with microphthalmia and dermal aplasia as part of the MIDAS syndrome [Happle et al., 1993]; 18q21.3 in a 12-year-old child with autism, anophthalmia, microphthalmia, and sclerocornea and a mutation in the RAX gene [Voronina et al., 2004]; and 6p22-24 in a dysmorphic infant with an interstitial deletion [Moriarty and Kerr-Muir, 1992].

The finding of sclerocornea in association with the chromosome 22q11.2 deletion syndrome suggests that a genetic locus at 22q11.2 influences anterior segment embryogenesis. The anterior segment of the eye includes the cornea, anterior chamber, iris, lens, ciliary body, and related structures. The embryologic basis for sclerocornea lies in the absence of normal migration of neural crest cells between weeks seven and ten of gestation. Lack of migration results in failure of formation of the limbal anlage, resulting in absence of the limbus, lack of differentiation between corneal and scleral architecture, and development of corneal opacification and flattening. [Friedman et al., 1975; Townsend, 1998] The link between the 22q11.2 deletion and anterior segment embryogenesis is also supported by a recent report of Peter anomaly in a patient with a 22q11.2 deletion. [Casteels and Devriendt, 2005] Further, posterior embryotoxon has been reported to be the most common ocular finding in patients with the chromosome 22q11.2 deletion syndrome, present in half of patients. [Forbes et al., 2006] Posterior embryotoxon is characterized by an anteriorly displaced and thickened Schwalbe’s ring, which is the anterior boundary of the trabecular meshwork and the posterior boundary of Descemet’s membrane, and is seen at greater frequency in patients with anterior segment dysgenesis anomalies (e.g., Axenfeld anomaly and Rieger syndrome). It is possible that 22q11.2 and the other genetic loci reported in association with sclerocornea play multifactorial and interrelated roles in neural crest migration and differentiation.

Based upon our report of isolated cases from multiple hospitals, it is not possible to accurately report the prevalence of sclerocornea in patients with the 22q11.2 deletion syndrome. However, sclerocornea is likely to be infrequent, as it was not an identified ocular finding in a recent series of 90 patients with the 22q11.2 deletion at the Children’s Hospital of Philadelphia. [Forbes et al., 2006]. Extrapolating upon the number of patients with 22q11.2 deletion syndrome examined by one of the ophthalmologist authors (B. J. F.), we estimate the prevalence of sclerocornea to be approximately 1 in 240 patients.

Treatment of sclerocornea is often complex, and outcomes may be poor. Correction of refractive errors, monitoring and treatment of amblyopia, clearing of central opacification via corneal transplantation, treatment of glaucoma, and management of other associated ocular abnormalities result in lifelong relationships with many different ophthalmic subspecialists. Allografts have a high rate of rejection in the cases of sclerocornea, especially when performed in the pediatric population, and the treatment of glaucoma in these cases is most often surgical due to abnormalities of the anterior chamber angle, which contains the aqueous outflow tracts of the eye. [Gregersen, 1981; Kampik et al., 1986] In six of our seven reported patients, the 22q11.2 genetic diagnostic process was already underway. However, in one patient (Patient 3) the 22q11.2 deletion was not suspected until after the child had already been undergoing treatment for sclerocornea for 2 years, including bilateral corneal transplantation. The delay in diagnosis in this case underscores the importance of recognizing this new syndromic association for sclerocornea and ensuring that pediatric ophthalmologists ask appropriate questions to determine if a systemic evaluation is indicated. Sclerocornea should be added to the clinical manifestations of the 22q11.2 deletion syndrome, and ophthalmologists diagnosing sclerocornea in children with systemic findings suggestive of 22q11.2 deletion should ensure appropriate genetic referral.

Acknowledgments

Heed Ophthalmic Foundation.

Footnotes

Data from this study were presented at the American Association of Pediatric Ophthalmology and Strabismus Annual Meeting in Keystone, Colorado, March 2006 and the Fifth International 22q11.2 Deletion Syndrome Conference, Marseilles, France, July 2006.

References

  • Bassett AS, Chow EW, Husted J, Weksberg R, Caluseriu O, Webb GD, Gatzoulis MA. Clinical features of 78 adults with 22q11 deletion syndrome. Am J Med Genet Part A. 2005;138A:307–313. [PMC free article] [PubMed]
  • Beemer FA, de Nef JJ, Delleman JW, Bleeker-Wagemakers EM, Shprintzen RJ. Additional eye findings in a girl with the velo-cardio-facial syndrome. Am J Med Genet. 1986;24:541–542. [PubMed]
  • Bloch N. Les differents types de sclerocornáee, leurs modes d’hereditáe et les malformations congáenitales concomitantes. J Genet Hum. 1965;14:133–172. [PubMed]
  • Casteels I, Devriendt K. Unilateral Peter anomaly in a patient with DiGeorge syndrome. J Pediatr Ophthalmol Strabismus. 2005;42:311–313. [PubMed]
  • Desvignes P, Pouliquen Y, Legras M, Guyot JD. Aspect iconographique d’une cornea plana dans une maladie de Lobstein. Arch Ophthalmol. 1967;27:585–592. [PubMed]
  • Devriendt K, Fryns JP, Mortier G. The annual incidence of DiGeorge/velocardiofacial syndrome. J Med Genet. 1998;35:789–790. [PMC free article] [PubMed]
  • Driscoll DA, Salvin J, Sellinger B, Budarf ML, McDonald-McGinn DM, Zackai EH, Emanuel BS. Prevalence of 22q11 microdeletions in DiGeorge and velocardiofacial syndromes: Implications for genetic counselling and prenatal diagnosis. J Med Genet. 1993;30:813–817. [PMC free article] [PubMed]
  • Eliott JH, Ferman SS, O’Day DM, Garber M. Hereditary sclerocornea. Arch Ophthalmol. 1985;103:676–679. [PubMed]
  • Fitch N. Velo-cardio-facial syndrome and eye abnormality [letter] Am J Med Genet. 1983;15:669.
  • Forbes BJ, Binenbaum G, Edmund JC, Delarato N, McDonald-McGinn DM, Zackai EH. Ocular findings in the chromosome 22q11.2 deletion syndrome. J AAPOS. 2006 (in press) [PubMed]
  • Friedman AH, Weingeist S, Brackup A, Marinoff G. Sclerocornea and defective mesodermal migration. Br J Ophthalmol. 1975;59:638. [PMC free article] [PubMed]
  • Gregersen E. Keratoplasty in babies with sclerocornea: To do or not to do? Report of an unsuccessful case. Dev Ophthalmol. 1981;5:52. [PubMed]
  • Happle R, Daniels O, Koopman RJJ. MIDAS syndrome (microphthalmia, dermal aplasia, and sclerocornea): An X-linked phenotype distinct from Goltz syndrome. Am J Med Genet. 1993;47:710–713. [PubMed]
  • Howard RO, Abrahams IW. Sclerocornea. Am J Ophthalmol. 1971;71:1254. [PubMed]
  • Kampik A, Lund OE, Halbig W. Penetrating keratoplasty in congenital corneal opacities. Klin Monatsbl Augenheilkd. 1986;188:188–192. [PubMed]
  • LaCassie Y, Arriaza MI. Opitz GBBB syndrome and the 22q11 deletion syndrome [letter] Am J Med Genet. 1996;62:318. [PubMed]
  • Mansour AM, Goldberg RB, Wang FM, Shprintzen RJ. Ocular findings in the velocardial facial syndrome. J Pediatr Ophthalmol Strabismus. 1987;24:263–266. [PubMed]
  • Matsuoka R, Takao A, Kimura M, Imamura S, Kondo C, Joh-o K, Ikeda K, Nishibatake M, Ando M, Momma K. Confirmation that the conotruncal anomaly face syndrome is associated with a deletion within 22q11.2. Am J Med Genet. 1994;53:285–289. [PubMed]
  • McDonald-McGinn DM, Driscoll DA, Bason L, Christensen K, Lynch D, Sullivan K, Canning D, Zavod W, Quinn N, Rome J. Autosomal dominant “Opitz” GBBB syndrome due to a 22q11. 2 deletion. Am J Med Genet. 1995;59:103–113. [PubMed]
  • McDonald-McGinn DM, Driscoll DA, Emanuel BS, Christensen K, Lynch D, Sullivan K, Canning D, Zavod W, Quinn N, Rome J. The 22q11 deletion in African-American patients: An underdiagnosed population. Am J Hum Genet. 1996;59:A90.
  • McDonald-McGinn DM, LaRossa D, Goldmuntz E, Sullivan K, Eicher P, Gerdes M, Moss E, Wang P, Solot C, Schultz P, Lynch D, Bingham P, Keenan G, Weinzimer S, Ming JE, Driscoll D, Clark BJ, 3rd, Markowitz R, Cohen A, Moshang T, Pasquariello P, Randall P, Emanuel BS, Zackai EH. The 22q11.2 Deletion: Screening, diagnostic work up, and outcome of results; report of 181 patients. Genetic Test. 1997;1:99–108. [PubMed]
  • McDonald-McGinn DM, Zackai EH, Low D. What’s in a name? The 22q11.2 deletion [letter] Am J Med Genet. 1997;72:247–249. [PubMed]
  • McDonald-McGinn DM, Kirschner R, Goldmuntz E, Sullivan K, Eicher P, Gerdes M, Moss E, Solot C, Wang P, Jacobs I, Handler S, Knightly C, Heher K, Wilson M, Ming JE, Grace K, Driscoll D, Pasquariello P, Randall P, Larossa D, Emanuel BS, Zackai EH. The Philadelphia story: The 22q11.2 deletion: Report on 250 patients. Genet Couns. 1999;10:11–24. [PubMed]
  • McDonald-McGinn DM, Tonnesen MK, Laufer-Cahana A, Finucane B, Driscoll DA, Emanuel BS, Zackai EH. Phenotype of the 22q11.2 deletion in individuals identified through an affected relative: Cast a wide FISHing net. Genet Med. 2001;3:23–29. [PubMed]
  • McDonald-McGinn DM, Minugh-Purvis N, Kirschner RE, Jawad A, Tonnesen MK, Catanzaro JR, Goldmuntz E, Driscoll D, Larossa D, Emanuel BS, Zackai EH. The 22q11.2 deletion in African-American patients: An underdiagnosed population? Am J Med Genet Part A. 2005;134A:242–246. [PMC free article] [PubMed]
  • McDonald-McGinn DM, Emanuel BS, Zackai EH. 22q11.2 Deletion Syndrome. 2006. [Accessed Feb 2006]. www.genetests.org.
  • Moriarty AP, Kerr-Muir MG. Sclerocornea and interstitial deletion of the short arm of chromosome 6–(46XY del[6] [p22 p24]) J Pediatr Ophthalmol Strabismus. 1992;29:177–179. [PubMed]
  • Oskarsdottir S, Vujic M, Fasth A. Incidence and prevalence of the 22q11 deletion syndrome: A population-based study in Western Sweden. Arch Dis Child. 2004;89:148–151. [PMC free article] [PubMed]
  • Ryan AK, Goodship JA, Wilson DI, Philip N, Levy A, Seidel H, Schuffenhauer S, Oechsler H, Belohradsky B, Prieur M, Aurias A, Raymond FL, Clayton-Smith J, Hatchwell E, McKeown C, Beemer FA, Dallapiccola B, Novelli G, Hurst JA, Ignatius J, Green AJ, Winter RM, Brueton L, Brondum-Nielsen K, Scambler PJ. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: A European collaborative study. J Med Genet. 1997;34:798–804. [PMC free article] [PubMed]
  • Shprintzen RJ, Wang F, Goldberg R, Marion R. The expanded velo-cardio-facial syndrome (VCF): Additional features of the most common clefting syndrome. Am J Hum Genet. 1985;37:A77.
  • Sullivan KE. The clinical, immunological, and molecular spectrum of chromosome 22q11.2 deletion syndrome and DiGeorge syndrome. Curr Opin Allergy Clin Immunol. 2004;4:505–512. [PubMed]
  • Tahvanainen E, Forsius H, Karila E, Ranta S, Eerola M, Weissenbach J, Sistonen P, de la Chapelle A. Cornea plana congenita gene assigned to the long arm of chromosome 12 by linkage analysis. Genomics. 1995;26:290–293. [PubMed]
  • Townsend WM. Congential corneal opacification. In: Kaufman HE, Barron BA, McDonald MB, editors. The Cornea. 2. Boston: Butterworth-Heinmann; 1998. pp. 371–373.
  • Voronina VA, Kozhemyakina EA, O’Kernick CM, Kahn ND, Wenger SL, Linberg JV, Schneider AS, Mathers PH. Mutations in the human RAX homeobox gene in a patient with anophthalmia and sclerocornea. Hum Mol Genet. 2004;13:315–322. [PubMed]
  • Wilson DI, Burn J, Scambler P, Goodship J. DiGeorge syndrome: Part of CATCH 22. J Med Genet. 1993;30:852–856. [PMC free article] [PubMed]
  • Wulfsberg EA, Leana-Cox J, Neri G. What’s in a name? Chromosome 22q abnormalities and the DiGeorge, velocardiofacial, and conotruncal anomalies face syndromes. Am J Med Genet. 1996;65:317–319. [PubMed]